Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations

Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations

<p>Abstract</p> <p>Background</p> <p>Highly selective antiretroviral (ARV) regimens such as single dose nevirapine (NVP) used for prevention of mother to child transmission (PMTCT) in resource-limited settings produce transient increases in otherwise marginal subpopulat...

Full description

Bibliographic Details
Main Authors:	Shiri Tinevimbo, Welte Alex
Format:	Article
Language:	English
Published:	BMC 2008-11-01
Series:	Theoretical Biology and Medical Modelling
Online Access:	http://www.tbiomed.com/content/5/1/25

Similar Items

In-vivo dynamics of HIV-1 evolution
by: Shiri, Tinevimbo
Published: (2011)

Trends in antiretroviral therapy and prevalence of HIV drug resistance mutations in Sweden 1997-2011.
by: Irene Bontell, et al.
Published: (2013-01-01)

Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease
by: Pierre Laville, et al.
Published: (2021-01-01)

Geolocalization of HIV-1 subtypes and resistance mutations of patients failing antiretroviral therapy in Salvador – Brazil
by: Antonio Walter de Oliveira Filho, et al.
Published: (2017-05-01)

Optimal control of combined therapy in a single strain HIV-1 model
by: Winston Garira, et al.
Published: (2005-05-01)

Analysis of the frequency of formation of HIV mutations associated with resistance to antiretroviral drugs
by: M.G. Liulchuk, et al.
Published: (2020-09-01)

HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China
by: Miaomiao Li, et al.
Published: (2021-02-01)

THE PREVALENCE OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WITH LOW ADHERENCE TO ANTIRETROVIRAL THERAPY IN THE LENINGRAD REGION
by: A. N. Shchemelev, et al.
Published: (2018-12-01)

Nationwide Study of Drug Resistance Mutations in HIV-1 Infected Individuals under Antiretroviral Therapy in Brazil
by: Ana Santos-Pereira, et al.
Published: (2021-05-01)

Somatic mutations substantially increase the per‐generation mutation rate in the conifer Picea sitchensis
by: Vincent C. T. Hanlon, et al.
Published: (2019-08-01)

Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India
by: S. Sinha, et al.
Published: (2012-01-01)

Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy
by: Xiao-lu Luo, et al.
Published: (2019-04-01)

Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
by: Aya Saleh, et al.
Published: (2021-07-01)

The Emergence of HIV-1 Transmitted Drug Resistance Mutations Among Antiretroviral Therapy-naive Individuals in Buleleng, Bali, Indonesia
by: Ni Luh Ayu Megasari, et al.
Published: (2019-11-01)

Development and evaluation of the oligonucleotide ligation assay (OLA) for the detection of drug resistance mutations in HIV-2 patients on antiretroviral therapy
by: Vanham Guido, et al.
Published: (2006-12-01)

HIV Drug Resistance-Associated Mutations in Antiretroviral Naïve HIV-1-Infected Latin American Children
by: Luis E. Soto-Ramirez, et al.
Published: (2010-01-01)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
by: Hellen Musana, et al.
Published: (2021-04-01)

Antiretroviral Drug Resistance Mutations among HIV Treatment Failure Patients in Tehran, Iran
by: Molood FARROKHI, et al.
Published: (2017-09-01)

Accelerating cancer without mutations
by: Douglas E Brash
Published: (2019-03-01)

Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia
by: Suharni Mohamad, et al.

Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia
by: Suharni Mohamad, et al.
Published: (2012-05-01)

HIV-1 genetic diversity and primary drug resistance mutations before large-scale access to antiretroviral therapy, Republic of Congo
by: Fabien Roch Niama, et al.
Published: (2017-07-01)

Paraconsistents artificial neural networks applied to the study of mutational patterns of the F subtype of the viral strains of HIV-1 to antiretroviral therapy
by: PAULO C.C. DOS SANTOS, et al.
Published: (2016-03-01)

High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil
by: Yury Oliveira Chaves, et al.
Published: (2021-01-01)

The Evolving Genotypic Profile of HIV-1 Mutations Related to Antiretroviral Treatment in the North Region of Brazil
by: Carmen Andréa F. Lopes, et al.
Published: (2015-01-01)

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.
by: Pierre Delobel, et al.
Published: (2011-01-01)

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy
by: Zhiyong Zhou, et al.
Published: (2018-05-01)

Substantial improvement of toyocamycin production in Streptomyces diastatochromogenes by cumulative drug-resistance mutations.
by: Xu-Ping Shentu, et al.
Published: (2018-01-01)

HIV-1 mutational pathways under multidrug therapy
by: Sönnerborg Anders, et al.
Published: (2011-07-01)

Genotypic resistance mutations to antiretroviral drugs in HIV-1 B and non-B subtypes from Cuba
by: Ruibal-Brunet Ignacio J., et al.
Published: (2001-01-01)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
by: Shaili Gupta, et al.
Published: (2014-09-01)

Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.
by: Holly E Rawizza, et al.
Published: (2013-01-01)

Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types
by: Joshua Yi Yeo, et al.
Published: (2021-12-01)

Common Β- Thalassaemia Mutations in
by: P Azarfam, et al.
Published: (2005-01-01)

The Dominance of CRF01_AE and the Emergence of Drug Resistance Mutations Among Antiretroviral Therapy-Experienced, HIV-1-infected Individuals in Medan, Indonesia
by: Dwi Wahyu Indriati, et al.
Published: (2020-12-01)

Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa.
by: Theresa M Rossouw, et al.
Published: (2015-01-01)

Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy
by: Judith N. Torimiro, et al.
Published: (2018-12-01)

False-negative errors in next-generation sequencing contribute substantially to inconsistency of mutation databases.
by: Young-Ho Kim, et al.
Published: (2019-01-01)

Substantial improvement of tetraene macrolide production in Streptomyces diastatochromogenes by cumulative drug resistance mutations.
by: Jing-Xuan Fan, et al.
Published: (2020-01-01)

Substantial unexplained variation in cancer risks for MLH1 and MSH2 mutation carriers
by: Dowty JG, et al.
Published: (2012-04-01)